miR-192 also benefits the prognosis of colon cancer patients by regulating SRPX2 [39], Rab-2A [40], RhoA-ROCK-LIMK2 [41], farnesoid X receptor [42], RB1/E2F1 pathway [43], and NOD2 [44]. Here, SRPX2 is linked to malignant colon neoplasm.